1. Home
  2. GCTK vs ENSC Comparison

GCTK vs ENSC Comparison

Compare GCTK & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GlucoTrack Inc.

GCTK

GlucoTrack Inc.

HOLD

Current Price

$0.81

Market Cap

1.4M

Sector

Health Care

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$0.38

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCTK
ENSC
Founded
2001
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4M
1.7M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
GCTK
ENSC
Price
$0.81
$0.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.8M
217.2K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
31.22
N/A
Revenue
$589,462.00
N/A
Revenue This Year
N/A
$55.01
Revenue Next Year
N/A
$1,033.97
P/E Ratio
$0.03
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.31
52 Week High
$15.90
$2.75

Technical Indicators

Market Signals
Indicator
GCTK
ENSC
Relative Strength Index (RSI) 44.93 39.10
Support Level $0.64 $0.31
Resistance Level $1.02 $0.63
Average True Range (ATR) 0.13 0.04
MACD 0.04 -0.01
Stochastic Oscillator 23.08 22.62

Price Performance

Historical Comparison
GCTK
ENSC

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: